<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ULORIC- febuxostat tablet </strong><br>Rebel Distributors Corp<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC.<br> <br> ULORIC (febuxostat) tablet for oral use<br>Initial U.S. Approval: 2009</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ULORIC is a xanthine oxidase (XO) inhibitor indicated for the chronic management of <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> in patients with <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>. (<a href="#i4i_indications_id_0eb5ce10-e52d-4a33-901f-40ed9c9ac1d4">1</a>) </p>
<p class="Highlighta">ULORIC is not recommended for the treatment of asymptomatic <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>. (<a href="#i4i_indications_id_0eb5ce10-e52d-4a33-901f-40ed9c9ac1d4">1</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>ULORIC is recommended at 40 mg or 80 mg once daily. The recommended starting dose of ULORIC is 40 mg once daily. For patients who do not achieve a serum uric acid (sUA) less than 6 mg per dL after 2 weeks with 40 mg, ULORIC 80 mg is recommended. (<a href="#i4i_section_id_fcee3d2b-f8e8-418e-959a-84e6c59071e9">2.1</a>)</li>
<li>ULORIC can be administered without regard to food or antacid use. (<a href="#i4i_section_id_fcee3d2b-f8e8-418e-959a-84e6c59071e9">2.1</a>)</li>
<li>No dose adjustment is necessary when administering ULORIC to patients with mild to moderate renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#i4i_section_id_2ea1ed67-e996-48f9-ba98-fc4fb90117e8">2.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablet: 40 mg, 80 mg. (<a href="#i4i_dosage_form_strength_id_eb1482e0-1d50-47c3-b412-399a3c020ead">3</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">ULORIC is contraindicated in patients being treated with azathioprine, mercaptopurine, or theophylline. (<a href="#i4i_contraindications_id_2487002e-089a-44b2-94e8-355979756f50">4</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flare</span></span>: An increase in <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> is frequently observed during initiation of anti-hyperuricemic agents, including ULORIC. If a <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flare</span> occurs during treatment, ULORIC need not be discontinued. <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> therapy (i.e., non-steroidal anti-inflammatory drug (NSAID) or colchicine upon initiation of treatment) may be beneficial for up to six months. (<a href="#i4i_section_id_6f6ba419-96f9-47e4-b5b1-8de7522c2952">2.4</a>, <a href="#i4i_section_id_6d8f539c-6e4a-4d0a-acaa-fb75c50b8567">5.1</a>)</li>
<li>
<span class="Underline">Cardiovascular Events</span>: A higher rate of cardiovascular <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> was observed in patients treated with ULORIC than allopurinol in clinical trials. Monitor for signs and symptoms of MI and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. (<a href="#i4i_section_id_de6dfd1b-ed8c-4102-92e7-cc58422847c9">5.2</a>)</li>
<li>
<span class="Underline">Liver Enzyme Elevation: </span>Transaminase elevations have been observed in ULORIC-treated patients. Monitor liver function tests periodically. (<a href="#i4i_section_id_f9d4622a-fd64-4f8e-a8a4-cc3acd125ffb">5.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Adverse reactions occurring in at least 1% of ULORIC-treated patients, and, at least 0.5% greater than placebo, are liver function abnormalities, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. (<a href="#i4i_section_id_4feab74b-d02c-4263-9094-9d4317caf29f">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-877-825-3327 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Concomitant administration of ULORIC with XO substrate drugs, azathioprine, mercaptopurine, or theophylline could increase plasma concentrations of these drugs resulting in severe toxicity. (<a href="#i4i_interactions_id_1a905816-1e15-42e8-9b1a-048444e9fa25">7</a>) </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>There is insufficient data in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. No studies have been conducted in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Caution should be exercised in these patients. (<a href="#i4i_section_id_b632c0ff-baf5-4295-9e27-05718dc42e69">8.6</a>, <a href="#i4i_section_id_3a741adc-eac0-4e37-a156-fc6728306399">8.7</a>)</li>
<li>No studies have been conducted in patients with secondary <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> (including patients being treated for Lesch-Nyhan syndrome or malignant disease, or in organ transplant recipients); therefore, ULORIC is not recommended for use in these patients. (<a href="#i4i_section_id_7948a211-3540-445e-bd2e-f1c6bd6765c1">8.8</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div><div><div></div></div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION, FDA-approved patient labeling, and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 12/2009</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Special Populations </a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Uric Acid Level</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flare</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Cardiovascular Events</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Liver Enzyme Elevations</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Xanthine Oxidase Substrate Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Cytotoxic Chemotherapy Drugs</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 <span class="Italics">In Vivo</span> Drug Interaction Studies</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 Secondary <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Management of <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> in <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 General Information</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_0eb5ce10-e52d-4a33-901f-40ed9c9ac1d4"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">ULORIC<span class="Sup">®</span> is a xanthine oxidase (XO) inhibitor indicated for the chronic management of <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> in patients with <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>.</p>
<p>ULORIC is not recommended for the treatment of asymptomatic <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_5ee21394-b77d-4e71-81da-abe4bf04b675"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fcee3d2b-f8e8-418e-959a-84e6c59071e9"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dose</h2>
<p class="First">For treatment of <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> in patients with <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, ULORIC is recommended at 40 mg or 80 mg once daily.</p>
<p>The recommended starting dose of ULORIC is 40 mg once daily. For patients who do not achieve a serum uric acid (sUA) less than 6 mg per dL after 2 weeks with 40 mg, ULORIC 80 mg is recommended. </p>
<p>ULORIC can be taken without regard to food or antacid use <span class="Italics">[see <a href="#i4i_pharmacokinetics_id_599d543b-d575-4fb7-b294-469c0465f6cf">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2ea1ed67-e996-48f9-ba98-fc4fb90117e8"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Special Populations </h2>
<p class="First">No dose adjustment is necessary when administering ULORIC in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#i4i_section_id_b632c0ff-baf5-4295-9e27-05718dc42e69">Use in Specific Populations (8.6)</a> and <a href="#i4i_pharmacokinetics_id_599d543b-d575-4fb7-b294-469c0465f6cf">Clinical Pharmacology (12.3)</a>].</span> The recommended starting dose of ULORIC is 40 mg once daily. For patients who do not achieve a sUA less than 6 mg per dL after 2 weeks with 40 mg, ULORIC 80 mg is recommended. </p>
<p> No dose adjustment is necessary in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#i4i_section_id_3a741adc-eac0-4e37-a156-fc6728306399">Use in Specific Populations (8.7)</a> and <a href="#i4i_pharmacokinetics_id_599d543b-d575-4fb7-b294-469c0465f6cf">Clinical Pharmacology (12.3)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fb267069-2471-4013-9ec0-925e15381cc2"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Uric Acid Level</h2>
<p class="First">Testing for the target serum uric acid level of less than 6 mg per dL may be performed as early as 2 weeks after initiating ULORIC therapy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6f6ba419-96f9-47e4-b5b1-8de7522c2952"></a><a name="section-2.4"></a><p></p>
<h2>2.4 <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout flares</span> may occur after initiation of ULORIC due to changing serum uric acid levels resulting in mobilization of urate from tissue deposits. Flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended upon initiation of ULORIC. <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> therapy may be beneficial for up to six months <span class="Italics">[see <a href="#i4i_section_id_8c49e13a-8c1f-4d61-bd86-2eec3d56259a">Clinical Studies (14.1)</a>]</span>.</p>
<p>If a <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flare</span> occurs during ULORIC treatment, ULORIC need not be discontinued. The <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flare</span> should be managed concurrently, as appropriate for the individual patient <span class="Italics">[see <a href="#i4i_section_id_6d8f539c-6e4a-4d0a-acaa-fb75c50b8567">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_eb1482e0-1d50-47c3-b412-399a3c020ead"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul>
<li>40 mg tablets, light green to green, round shaped, debossed with "TAP" and "40"</li>
<li>80 mg tablets, light green to green, teardrop shaped, debossed with "TAP" and "80"</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_2487002e-089a-44b2-94e8-355979756f50"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">ULORIC is contraindicated in patients being treated with azathioprine, mercaptopurine, or theophylline <span class="Italics">[see <a href="#i4i_interactions_id_1a905816-1e15-42e8-9b1a-048444e9fa25">Drug Interactions (7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_ad2e3e2f-b908-4943-b5f2-63ed2c438944"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6d8f539c-6e4a-4d0a-acaa-fb75c50b8567"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flare</span></h2>
<p class="First">After initiation of ULORIC, an increase in <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> is frequently observed. This increase is due to reduction in serum uric acid levels resulting in mobilization of urate from tissue deposits. </p>
<p>In order to prevent <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> when ULORIC is initiated, concurrent <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment with an NSAID or colchicine is recommended <span class="Italics">[see <a href="#i4i_section_id_6f6ba419-96f9-47e4-b5b1-8de7522c2952">Dosage and Administration (2.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_de6dfd1b-ed8c-4102-92e7-cc58422847c9"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Cardiovascular Events</h2>
<p class="First">In the randomized controlled studies, there was a higher rate of cardiovascular <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> (cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>, and non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>) in patients treated with ULORIC [0.74 per 100 P-Y (95% CI 0.36-1.37)] than allopurinol [0.60 per 100 P-Y (95% CI 0.16-1.53)] <span class="Italics">[see <a href="#i4i_section_id_4feab74b-d02c-4263-9094-9d4317caf29f">Adverse Reactions (6.1)</a>]</span>. A causal relationship with ULORIC has not been established. Monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f9d4622a-fd64-4f8e-a8a4-cc3acd125ffb"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Liver Enzyme Elevations</h2>
<p class="First">During randomized controlled studies, transaminase elevations greater than 3 times the upper limit of normal (ULN) were observed (AST: 2%, 2%, and ALT: 3%, 2% in ULORIC and allopurinol-treated patients, respectively). No dose-effect relationship for these transaminase elevations was noted. Laboratory assessment of liver function is recommended at, for example, 2 and 4 months following initiation of ULORIC and periodically thereafter. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_7cf3b47b-349a-4a15-b07a-4958c644054f"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4feab74b-d02c-4263-9094-9d4317caf29f"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>A total of 2757 subjects with <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> and <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> were treated with ULORIC 40 mg or 80 mg daily in clinical studies. For ULORIC 40 mg, 559 patients were treated for ≥ 6 months. For ULORIC 80 mg, 1377 subjects were treated for ≥ 6 months, 674 patients were treated for ≥ 1 year and 515 patients were treated for ≥ 2 years. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f1641141-a992-4e70-b492-5428c5a4f993"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Most Common Adverse Reactions </span></p>
<p>In three randomized, controlled clinical studies (Studies 1, 2 and 3), which were 6 to 12 months in duration, the following adverse reactions were reported by the treating physician as related to study drug. Table 1 summarizes adverse reactions reported at a rate of at least 1% in ULORIC treatment groups and at least 0.5% greater than placebo. </p>
<a name="id_2f5b7c19-0df0-4ac3-8123-996e876e5f2b"></a><table>
<col align="left" width="20%">
<col align="center" width="19%">
<col align="center" width="19%">
<col align="center" width="19%">
<col align="center" width="23%">
<thead>
<tr class="First Toprule"><td class="Botrule Lrule Rrule" align="center" colspan="5" valign="top">Table 1: Adverse Reactions Occurring in ≥ 1% of ULORIC-Treated Patients and at Least 0.5% Greater than Seen in Patients Receiving Placebo in Controlled Studies</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top">Adverse Reactions</td>
<td class="Botrule Rrule" align="left" valign="top">  Placebo</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">ULORIC</td>
<td class="Botrule Lrule Rrule" align="left" valign="top">  allopurinol<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="center" valign="top">(N=134)</td>
<td class="Rrule" align="left" valign="top">40 mg daily<br>(N=757)</td>
<td class="Rrule" align="left" valign="top">80 mg daily<br>(N=1279)</td>
<td class="Rrule" align="left" valign="top">
<br>(N=1277)</td>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Of the subjects who received allopurinol, 10 received 100 mg, 145 received 200 mg, and 1122 received 300 mg, based on level of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. </dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top">Liver Function Abnormalities</td>
<td class="Rrule" align="left" valign="top">0.7%</td>
<td class="Rrule" align="left" valign="top">6.6%</td>
<td class="Rrule" align="left" valign="top">4.6%</td>
<td class="Rrule" align="left" valign="top">4.2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="left" valign="top">0.7%</td>
<td class="Rrule" align="left" valign="top">1.1%</td>
<td class="Rrule" align="left" valign="top">1.3%</td>
<td class="Rrule" align="left" valign="top">0.8%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> </td>
<td class="Rrule" align="left" valign="top">   0%</td>
<td class="Rrule" align="left" valign="top">1.1%</td>
<td class="Rrule" align="left" valign="top">0.7%</td>
<td class="Rrule" align="left" valign="top">0.7%</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="left" valign="top">0.7%</td>
<td class="Rrule" align="left" valign="top">0.5%</td>
<td class="Rrule" align="left" valign="top">1.6%</td>
<td class="Rrule" align="left" valign="top">1.6%</td>
</tr>
</tbody>
</table>
<p>The most common adverse reaction leading to discontinuation from therapy was liver function abnormalities in 1.8% of ULORIC 40 mg, 1.2% of ULORIC 80 mg, and in 0.9% of allopurinol-treated subjects. </p>
<p>In addition to the adverse reactions presented in Table 1, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> was reported in more than 1% of ULORIC-treated subjects although not at a rate more than 0.5% greater than placebo. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eb5f37a7-22a1-43e0-879f-de02f1e9e7ae"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Underline">Less Common Adverse Reactions</span></p>
<p>In phase 2 and 3 clinical studies the following adverse reactions occurred in less than 1% of subjects and in more than one subject treated with doses ranging from 40 mg to 240 mg of ULORIC. This list also includes adverse reactions (less than 1% of subjects) associated with organ systems from Warnings and Precautions.</p>
<p><span class="Italics">Blood and Lymphatic System Disorders</span>: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>/<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>/flutter, <span class="product-label-link" type="condition" conceptid="316822" conceptname="Heart murmur">cardiac murmur</span>, <span class="product-label-link" type="condition" conceptid="320536" conceptname="Electrocardiogram abnormal">ECG abnormal</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p><span class="Italics">Ear and Labyrinth Disorders</span>: <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span>: abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, frequent stools, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">gastrointestinal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4009488" conceptname="Sore gums">gingival pain</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">haematemesis</span>, <span class="product-label-link" type="condition" conceptid="4265627" conceptname="Hyperchlorhydria">hyperchlorhydria</span>, <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Italics">General Disorders and Administration Site Conditions</span>: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">feeling abnormal</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait disturbance</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms, <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>.</p>
<p><span class="Italics">Hepatobiliary Disorders</span>: <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>/<span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>, <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorder</span></span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span>: <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>. </p>
<p><span class="Italics">Procedural Complications</span>: <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">contusion</span>.</p>
<p><span class="Italics">Metabolism and Nutrition Disorders</span>: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">appetite decreased</span>/increased, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span>/increased. </p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="72404" conceptname="Joint stiffness">joint stiffness</span>, <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>/<span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>/tightness/<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>/<span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span>: altered taste, <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">balance disorder</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, Guillain-Barré syndrome, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4065756" conceptname="Hemiparesis">hemiparesis</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4307095" conceptname="Sense of smell impaired">hyposmia</span>, <span class="product-label-link" type="condition" conceptid="4046360" conceptname="Lacunar infarction">lacunar infarction</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="438409" conceptname="Attention deficit hyperactivity disorder">mental impairment</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, transient ischemic attack, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.</p>
<p><span class="Italics">Psychiatric Disorders</span>: <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">libido decreased</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality change</span>. </p>
<p><span class="Italics">Renal and Urinary Disorders</span>: <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">pollakiuria</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, urgency, <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>.</p>
<p><span class="Italics">Reproductive System and Breast Changes</span>: <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>. </p>
<p><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4171214" conceptname="Nasal mucosa dry">nasal dryness</span>, paranasal sinus hypersecretion, <span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">pharyngeal edema</span>, <span class="product-label-link" type="condition" conceptid="4170108" conceptname="Respiratory tract congestion">respiratory tract congestion</span>, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>. </p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders</span>: <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, angio-<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="132983" conceptname="Dermatographic urticaria">dermographism</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="4242607" conceptname="Hair discoloration">hair color changes</span>, <span class="product-label-link" type="condition" conceptid="4309771" conceptname="Abnormal hair growth">hair growth abnormal</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span><span class="Italics">,</span> <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> skin, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>/altered <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesion</span>, <span class="product-label-link" type="condition" conceptid="4178504" conceptname="Body odor">skin odor abnormal</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. </p>
<p><span class="Italics">Laboratory Parameters:</span> <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span> prolonged, creatine increased, <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> decreased, sodium increased, <span class="product-label-link" type="condition" conceptid="4168553" conceptname="Electroencephalogram abnormal">EEG abnormal</span>, glucose increased, <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> increased, triglycerides increased, amylase increased, potassium increased, TSH increased, platelet count decreased, <span class="product-label-link" type="condition" conceptid="4216894" conceptname="Precipitous drop in hematocrit">hematocrit decreased</span>, <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">hemoglobin decreased</span>, MCV increased, <span class="product-label-link" type="condition" conceptid="4013842" conceptname="RBC count low">RBC decreased</span>, creatinine increased, blood urea increased, BUN/creatinine ratio increased, creatine phosphokinase (CPK) increased, alkaline phosphatase increased, LDH increased, <span class="product-label-link" type="condition" conceptid="4245252" conceptname="Raised prostate specific antigen">PSA increased</span>, urine output increased/decreased, lymphocyte count decreased, neutrophil count decreased, WBC increased/decreased, coagulation test abnormal, low density lipoprotein (LDL) increased, <span class="product-label-link" type="condition" conceptid="4260197" conceptname="Prothrombin time increased">prothrombin time prolonged</span>, <span class="product-label-link" type="condition" conceptid="442282" conceptname="Urinary casts">urinary casts</span>, urine positive for white blood cells and protein.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9cc20a61-1082-47d8-b946-83f5c58bfd68"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold">Cardiovascular Safety </span></p>
<p>Cardiovascular events and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were adjudicated to one of the pre-defined endpoints from the Anti-Platelet Trialists' Collaborations (APTC) (cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>) in the randomized controlled and long-term extension studies. In the Phase 3 randomized controlled studies, the incidences of adjudicated APTC events per 100 patient-years of exposure were: Placebo 0 (95% CI 0.00-6.16), ULORIC 40 mg 0 (95% CI 0.00-1.08), ULORIC 80 mg 1.09 (95% CI 0.44-2.24), and allopurinol 0.60 (95% CI 0.16-1.53).</p>
<p>In the long-term extension studies, the incidences of adjudicated APTC events were: ULORIC 80 mg 0.97 (95% CI 0.57-1.56), and allopurinol 0.58 (95% CI 0.02-3.24).</p>
<p>Overall, a higher rate of APTC events was observed in ULORIC than in allopurinol-treated patients. A causal relationship with ULORIC has not been established. Monitor for signs and symptoms of MI and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_1a905816-1e15-42e8-9b1a-048444e9fa25"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_00d82bf4-d526-49ea-8eec-07206fa2ae97"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Xanthine Oxidase Substrate Drugs</h2>
<p class="First">ULORIC is an XO inhibitor. Drug interaction studies of ULORIC with drugs that are metabolized by XO (e.g., theophylline, mercaptopurine, azathioprine) have not been conducted. Inhibition of XO by ULORIC may cause increased plasma concentrations of these drugs leading to toxicity <span class="Italics">[see <a href="#i4i_pharmacokinetics_id_599d543b-d575-4fb7-b294-469c0465f6cf">Clinical Pharmacology (12.3)</a>]</span>. ULORIC is contraindicated in patients being treated with azathioprine, mercaptopurine, or theophylline <span class="Italics">[see <a href="#i4i_contraindications_id_2487002e-089a-44b2-94e8-355979756f50">Contraindications (4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_097216b7-d5c7-453c-aac8-9a694244f941"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Cytotoxic Chemotherapy Drugs</h2>
<p class="First">Drug interaction studies of ULORIC with cytotoxic chemotherapy have not been conducted. No data are available regarding the safety of ULORIC during cytotoxic chemotherapy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_deedec12-0cff-48eb-9610-e340fc6d07e4"></a><a name="section-7.3"></a><p></p>
<h2>7.3 <span class="Italics">In Vivo</span> Drug Interaction Studies</h2>
<p class="First">Based on drug interaction studies in healthy subjects, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine <span class="Italics">[see <a href="#i4i_pharmacokinetics_id_599d543b-d575-4fb7-b294-469c0465f6cf">Clinical Pharmacology (12.3)</a>]</span>. Therefore, ULORIC may be used concomitantly with these medications.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_85b1f258-f950-4efe-ad62-b9b218715a69"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_abc9a2df-aa3f-4e4a-989d-54df120fe8a8"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_207464fc-1e58-40e1-9d2e-e72a6b9ee352"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">Pregnancy Category C</span>: There are no adequate and well-controlled studies in pregnant women. ULORIC should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
<p>Febuxostat was not teratogenic in rats and rabbits at oral doses up to 48 mg per kg (40 and 51 times the human plasma exposure at 80 mg per day for equal body surface area, respectively) during organogenesis. However, increased neonatal mortality and a reduction in the neonatal body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> were observed when pregnant rats were treated with oral doses up to 48 mg per kg (40 times the human plasma exposure at 80 mg per day) during organogenesis and through lactation period.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_a4550e96-f8af-4e7b-8271-b1d8fd4d61c1"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Febuxostat is excreted in the milk of rats. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ULORIC is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_dcdde18a-f712-407d-978c-74184d0623ae"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients under 18 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_9c12c786-23ba-4abc-9a9b-808528943250"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">No dose adjustment is necessary in elderly patients. Of the total number of subjects in clinical studies of ULORIC, 16 percent were 65 and over, while 4 percent were 75 and over. Comparing subjects in different age groups, no clinically significant differences in safety or effectiveness were observed but greater sensitivity of some older individuals cannot be ruled out. The C<span class="Sub">max</span> and AUC<span class="Sub">24</span> of febuxostat following multiple oral doses of ULORIC in geriatric subjects (≥ 65 years) were similar to those in younger subjects (18-40 years) <span class="Italics">[see <a href="#i4i_pharmacokinetics_id_599d543b-d575-4fb7-b294-469c0465f6cf">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b632c0ff-baf5-4295-9e27-05718dc42e69"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dose adjustment is necessary in patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (Cl<span class="Sub">cr</span> 30-89 mL per min). The recommended starting dose of ULORIC is 40 mg once daily. For patients who do not achieve a sUA less than 6 mg per dL after 2 weeks with 40 mg, ULORIC 80 mg is recommended. </p>
<p>There are insufficient data in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (Cl<span class="Sub">cr</span> less than 30 mL per min); therefore, caution should be exercised in these patients <span class="Italics">[see <a href="#i4i_pharmacokinetics_id_599d543b-d575-4fb7-b294-469c0465f6cf">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3a741adc-eac0-4e37-a156-fc6728306399"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dose adjustment is necessary in patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class A or B). No studies have been conducted in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C); therefore, caution should be exercised in these patients <span class="Italics">[see <a href="#i4i_pharmacokinetics_id_599d543b-d575-4fb7-b294-469c0465f6cf">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7948a211-3540-445e-bd2e-f1c6bd6765c1"></a><a name="section-8.7"></a><p></p>
<h2>8.8 Secondary <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span></h2>
<p class="First">No studies have been conducted in patients with secondary <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> (including organ transplant recipients); ULORIC is not recommended for use in patients whom the rate of urate formation is greatly increased (e.g., malignant disease and its treatment, Lesch-Nyhan syndrome). The concentration of xanthine in urine could, in rare cases, rise sufficiently to allow deposition in the urinary tract. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_aa7c7030-bf2b-443e-9096-47c676e586ab"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">ULORIC was studied in healthy subjects in doses up to 300 mg daily for seven days without evidence of dose-limiting toxicities. No <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of ULORIC was reported in clinical studies. Patients should be managed by symptomatic and supportive care should there be an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_32ab94e6-d67a-4d41-88ac-6517542fe3bb"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">ULORIC (febuxostat) is a xanthine oxidase inhibitor. The active ingredient in ULORIC is 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid, with a molecular weight of 316.38. The empirical formula is C<span class="Sub">16</span>H<span class="Sub">16</span>N<span class="Sub">2</span>O<span class="Sub">3</span>S. </p>
<p>The chemical structure is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ae1e0d8a-03fc-419b-9d44-afa68fbd5681&amp;name=ae1e0d8a-03fc-419b-9d44-afa68fbd5681-01.jpg"></div>
<p>Febuxostat is a non-hygroscopic, white crystalline powder that is freely soluble in dimethylformamide; soluble in dimethylsulfoxide; sparingly soluble in ethanol; slightly soluble in methanol and acetonitrile; and practically insoluble in water. The melting range is 205°C to 208°C. </p>
<p>ULORIC tablets for oral use contain the active ingredient, febuxostat, and are available in two dosage strengths, 40 mg and 80 mg. Inactive ingredients include lactose monohydrate, microcrystalline cellulose, hydroxypropyl cellulose, sodium croscarmellose, silicon dioxide and magnesium stearate. ULORIC tablets are coated with Opadry II, green.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_33de946b-4cf3-41a7-ab2d-fbc1c67323bc"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_2b91cc30-ad6f-4a19-8b77-c0f509ccf565"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">ULORIC, a xanthine oxidase inhibitor, achieves its therapeutic effect by decreasing serum uric acid. ULORIC is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_c6beacd3-f544-4683-9e7c-c1fcb25d39de"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_db902b4b-e03c-47b4-a8c7-0f174459a81b"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Italics">Effect on Uric Acid and Xanthine Concentrations</span>: In healthy subjects, ULORIC resulted in a dose dependent decrease in 24-hour mean serum uric acid concentrations, and an increase in 24-hour mean serum xanthine concentrations. In addition, there was a decrease in the total daily urinary uric acid excretion. Also, there was an increase in total daily urinary xanthine excretion. Percent reduction in 24-hour mean serum uric acid concentrations was between 40% to 55% at the exposure levels of 40 mg and 80 mg daily doses. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_96f38d53-f0b5-47ce-b0a3-24388701f848"></a><a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Italics">Effect on Cardiac Repolarization</span>: The effect of ULORIC on cardiac repolarization as assessed by the QTc interval was evaluated in normal healthy subjects and in patients with <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>. ULORIC in doses up to 300 mg daily, at steady state, did not demonstrate an effect on the QTc interval.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_599d543b-d575-4fb7-b294-469c0465f6cf"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">In healthy subjects, maximum plasma concentrations (C<span class="Sub">max</span>) and AUC of febuxostat increased in a dose proportional manner following single and multiple doses of 10 mg to 120 mg. There is no accumulation when therapeutic doses are administered every 24 hours. Febuxostat has an apparent mean terminal elimination half-life (t<span class="Sub">1/2</span>) of approximately 5 to 8 hours. Febuxostat pharmacokinetic parameters for patients with <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> and <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> estimated by population pharmacokinetic analyses were similar to those estimated in healthy subjects.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d317f6f0-f4ff-4fa5-a602-2b7518ed3c76"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Italics">Absorption:</span> The absorption of radiolabeled febuxostat following oral dose administration was estimated to be at least 49% (based on total radioactivity recovered in urine). Maximum plasma concentrations of febuxostat occurred between 1 to 1.5 hours post-dose. After multiple oral 40 mg and 80 mg once daily doses, C<span class="Sub">max</span> is approximately 1.6 ± 0.6 mcg per mL (N=30), and 2.6 ± 1.7 mcg per mL (N=227), respectively. Absolute bioavailability of the febuxostat tablet has not been studied. </p>
<p>Following multiple 80 mg once daily doses with a high fat meal, there was a 49% decrease in C<span class="Sub">max</span> and an 18% decrease in AUC, respectively. However, no clinically significant change in the percent decrease in serum uric acid concentration was observed (58% fed vs. 51% fasting). Thus, ULORIC may be taken without regard to food. </p>
<p>Concomitant ingestion of an antacid containing magnesium hydroxide and aluminum hydroxide with an 80 mg single dose of ULORIC has been shown to delay absorption of febuxostat (approximately 1 hour) and to cause a 31% decrease in C<span class="Sub">max</span> and a 15% decrease in AUC<span class="Sub">∞</span>. As AUC rather than C<span class="Sub">max</span> was related to drug effect, change observed in AUC was not considered clinically significant. Therefore, ULORIC may be taken without regard to antacid use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9422b0ab-a934-4f83-8b3f-7a2334771c01"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Italics">Distribution: </span>The mean apparent steady state volume of distribution (V<span class="Sub">ss</span>/F) of febuxostat was approximately 50 L (CV ~40%). The plasma protein binding of febuxostat is approximately 99.2%, (primarily to albumin), and is constant over the concentration range achieved with 40 mg and 80 mg doses. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0c81c5ec-66c6-4bf7-939b-0b9518fa6659"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Italics">Metabolism: </span>Febuxostat is extensively metabolized by both conjugation via uridine diphosphate glucuronosyltransferase (UGT) enzymes including UGT1A1, UGT1A3, UGT1A9, and UGT2B7 and oxidation via cytochrome P450 (CYP) enzymes including CYP1A2, 2C8 and 2C9 and non-P450 enzymes. The relative contribution of each enzyme isoform in the metabolism of febuxostat is not clear. The oxidation of the isobutyl side chain leads to the formation of four pharmacologically active hydroxy metabolites, all of which occur in plasma of humans at a much lower extent than febuxostat. </p>
<p>In urine and feces, acyl glucuronide metabolites of febuxostat (~35% of the dose), and oxidative metabolites, 67M-1 (~10% of the dose), 67M-2 (~11% of the dose), and 67M-4, a secondary metabolite from 67M-1, (~14% of the dose) appeared to be the major metabolites of febuxostat <span class="Italics">in vivo</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_512d0faf-ddd0-404b-b31a-9fd5509fb0f0"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Italics">Elimination: </span>Febuxostat is eliminated by both hepatic and renal pathways. Following an 80 mg oral dose of <span class="Sup">14</span>C-labeled febuxostat, approximately 49% of the dose was recovered in the urine as unchanged febuxostat (3%), the acyl glucuronide of the drug (30%), its known oxidative metabolites and their conjugates (13%), and other unknown metabolites (3%). In addition to the urinary excretion, approximately 45% of the dose was recovered in the feces as the unchanged febuxostat (12%), the acyl glucuronide of the drug (1%), its known oxidative metabolites and their conjugates (25%), and other unknown metabolites (7%).</p>
<p>The apparent mean terminal elimination half-life (t<span class="Sub">1/2</span>) of febuxostat was approximately 5 to 8 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_666b7dff-0632-48af-b2ea-6d4b50aea797"></a><a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Underline">Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0d8e0723-bc4d-4e05-851c-acde17e460f5"></a><a name="section-11.3.5.1"></a><p></p>
<p class="First"><span class="Italics">Pediatric Use: </span>The pharmacokinetics of ULORIC in patients under the age of 18 years have not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3b191c5c-7883-4ac9-a51c-9f76ebaa69d8"></a><a name="section-11.3.5.2"></a><p></p>
<p class="First"><span class="Italics">Geriatric Use: </span>The C<span class="Sub">max</span> and AUC of febuxostat and its metabolites following multiple oral doses of ULORIC in geriatric subjects (≥ 65 years) were similar to those in younger subjects (18-40 years). In addition, the percent decrease in serum uric acid concentration was similar between elderly and younger subjects. No dose adjustment is necessary in geriatric patients <span class="Italics">[see <a href="#i4i_geriatric_use_id_9c12c786-23ba-4abc-9a9b-808528943250">Use in Specific Populations (8.5)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cdac4d2d-7e55-44b3-a8c3-892c66b412ea"></a><a name="section-11.3.5.3"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: </span>Following multiple 80 mg doses of ULORIC in healthy subjects with mild (Cl<span class="Sub">cr</span> 50-80 mL per min), moderate (Cl<span class="Sub">cr</span> 30-49 mL per min) or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (Cl<span class="Sub">cr</span> 10-29 mL per min), the C<span class="Sub">max</span> of febuxostat did not change relative to subjects with normal renal function (Cl<span class="Sub">cr</span> greater than 80 mL per min). AUC and half-life of febuxostat increased in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> in comparison to subjects with normal renal function, but values were similar among three <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> groups. Mean febuxostat AUC values were up to 1.8 times higher in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared to those with normal renal function. Mean C<span class="Sub">max</span> and AUC values for 3 active metabolites increased up to 2- and 4-fold, respectively. However, the percent decrease in serum uric acid concentration for subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> was comparable to those with normal renal function (58% in normal renal function group and 55% in the severe renal function group). </p>
<p>No dose adjustment is necessary in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#i4i_dosage_admin_id_5ee21394-b77d-4e71-81da-abe4bf04b675">Dosage and Administration (2)</a> and <a href="#i4i_section_id_b632c0ff-baf5-4295-9e27-05718dc42e69">Use in Specific Populations (8.6)</a>]</span>. The recommended starting dose of ULORIC is 40 mg once daily. For patients who do not achieve a sUA less than 6 mg per dL after 2 weeks with 40 mg, ULORIC 80 mg is recommended. There is insufficient data in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>; caution should be exercised in those patients <span class="Italics">[see <a href="#i4i_section_id_b632c0ff-baf5-4295-9e27-05718dc42e69">Use in Specific Populations (8.6)</a>]</span>. </p>
<p>ULORIC has not been studied in end stage <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> patients who are on dialysis. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_924144b4-e354-4cff-8c7b-7c5728a7a316"></a><a name="section-11.3.5.4"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>: Following multiple 80 mg doses of ULORIC in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, an average of 20-30% increase was observed for both C<span class="Sub">max</span> and AUC<span class="Sub">24</span> (total and unbound) in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> groups compared to subjects with normal hepatic function. In addition, the percent decrease in serum uric acid concentration was comparable between different hepatic groups (62% in healthy group, 49% in mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> group, and 48% in moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> group). No dose adjustment is necessary in patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. No studies have been conducted in subjects with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C); caution should be exercised in those patients <span class="Italics">[see <a href="#i4i_section_id_3a741adc-eac0-4e37-a156-fc6728306399">Use in Specific Populations (8.7)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_42e0f606-064c-4bd2-8c2b-7c4dba773ec2"></a><a name="section-11.3.5.5"></a><p></p>
<p class="First"><span class="Italics">Gender: </span>Following multiple oral doses of ULORIC, the C<span class="Sub">max</span> and AUC<span class="Sub">24</span> of febuxostat were 30% and 14% higher in females than in males, respectively. However, weight-corrected C<span class="Sub">max</span> and AUC were similar between the genders. In addition, the percent decrease in serum uric acid concentrations was similar between genders. No dose adjustment is necessary based on gender.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_93faf44e-8b37-43f3-a5f8-70e5e33d1469"></a><a name="section-11.3.5.6"></a><p></p>
<p class="First"><span class="Italics">Race: </span>No specific pharmacokinetic study was conducted to investigate the effects of race.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1b286b68-bcb4-4169-9768-bcd46fb76845"></a><a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Underline">Drug-Drug Interactions</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4cebfe94-0869-4ef9-8358-6fa3c1d72af3"></a><a name="section-11.3.6.1"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics">Effect of ULORIC on Other Drugs</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_da334695-9f48-4a06-93bf-fca913044d56"></a><a name="section-11.3.6.1.1"></a><p></p>
<p class="First"><span class="Italics">Xanthine Oxidase Substrate Drugs-Azathioprine, Mercaptopurine, and Theophylline: </span>Febuxostat is an XO inhibitor. Drug interaction studies of ULORIC with drugs that are metabolized by XO (e.g., theophylline, mercaptopurine, azathioprine) have not been conducted. Inhibition of XO by ULORIC may cause increased plasma concentrations of these drugs leading to toxicity. ULORIC is contraindicated in patients being treated with azathioprine, mercaptopurine, and theophylline <span class="Italics">[see <a href="#i4i_contraindications_id_2487002e-089a-44b2-94e8-355979756f50">Contraindications (4)</a> and <a href="#i4i_interactions_id_1a905816-1e15-42e8-9b1a-048444e9fa25">Drug Interactions (7)</a>].</span></p>
<p>Azathioprine and mercaptopurine undergo metabolism via three major metabolic pathways, one of which is mediated by XO. Although ULORIC drug interaction studies with azathioprine and mercaptopurine have not been conducted, concomitant administration of allopurinol [a xanthine oxidase inhibitor] with azathioprine or mercaptopurine has been reported to substantially increase plasma concentrations of these drugs. Because ULORIC is a xanthine oxidase inhibitor, it could inhibit the XO-mediated metabolism of azathioprine and mercaptopurine leading to increased plasma concentrations of azathioprine or mercaptopurine that could result in severe toxicity. </p>
<p>Theophylline is a CYP1A2 and XO substrate. Although no ULORIC drug interaction study with theophylline has been conducted, concomitant administration of theophylline with allopurinol, a xanthine oxidase inhibitor at doses ≥ 600 mg per day, has been reported to increase theophylline plasma concentrations. Because ULORIC is a xanthine oxidase inhibitor and theophylline is a low therapeutic index drug, ULORIC could inhibit the XO-mediated metabolism of theophylline leading to increased plasma concentrations of theophylline that could induce severe theophylline toxicity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_40647f99-4b29-4b83-b6c8-8315e9da5ddb"></a><a name="section-11.3.6.1.2"></a><p></p>
<p class="First"><span class="Italics">P450 Substrate Drugs: In vitro </span>studies have shown that febuxostat does not inhibit P450 enzymes CYP1A2, 2C9, 2C19, 2D6, or 3A4 and it also does not induce CYP1A2, 2B6, 2C9, 2C19, or 3A4 at clinically relevant concentrations. As such, <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> between ULORIC and drugs metabolized by these CYP enzymes are unlikely.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_511642f0-5e77-4728-9c1a-2b95dfe816bf"></a><a name="section-11.3.6.2"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics">Effect of Other Drugs on ULORIC </span></span></p>
<p>Febuxostat is metabolized by conjugation and oxidation via multiple metabolizing enzymes. The relative contribution of each enzyme isoform is not clear. Drug interactions between ULORIC and a drug that inhibits or induces one particular enzyme isoform is in general not expected. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_731b4c36-0e9a-473f-abe0-f345058c1d20"></a><a name="section-11.3.6.3"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics">In Vivo Drug Interaction Studies</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fa187e8a-4907-4668-a33d-623814540f21"></a><a name="section-11.3.6.3.1"></a><p></p>
<p class="First"><span class="Italics">Colchicine:</span> No dose adjustment is necessary for either ULORIC or colchicine when the two drugs are co-administered. Administration of ULORIC (40 mg once daily) with colchicine (0.6 mg twice daily) resulted in an increase of 12% in C<span class="Sub">max</span> and 7% in AUC<span class="Sub">24</span> of febuxostat. In addition, administration of colchicine (0.6 mg twice daily) with ULORIC (120 mg daily) resulted in less than 11% change in C<span class="Sub">max</span> or AUC of colchicine for both AM and PM doses. These changes were not considered clinically significant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e076c801-1d2f-4573-b561-18c8032d2238"></a><a name="section-11.3.6.3.2"></a><p></p>
<p class="First"><span class="Italics">Naproxen:</span> No dose adjustment is necessary for ULORIC or naproxen when the two drugs are co-administered. Administration of ULORIC (80 mg once daily) with naproxen (500 mg twice daily) resulted in a 28% increase in C<span class="Sub">max </span>and a 40% increase in AUC of febuxostat. The increases were not considered clinically significant. In addition, there were no significant changes in the C<span class="Sub">max</span> or AUC of naproxen (less than 2%). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d366cf5b-9850-4b43-8a3d-d7538da11cbb"></a><a name="section-11.3.6.3.3"></a><p></p>
<p class="First"><span class="Italics">Indomethacin: </span>No dose adjustment is necessary for either ULORIC or indomethacin when these two drugs are co-administered. Administration of ULORIC (80 mg once daily) with indomethacin (50 mg twice daily) did not result in any significant changes in C<span class="Sub">max</span> or AUC of febuxostat or indomethacin (less than 7%). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_30bc8e6c-631f-41cd-b2b6-1dd44a3cd158"></a><a name="section-11.3.6.3.4"></a><p></p>
<p class="First"><span class="Italics">Hydrochlorothiazide: </span>No dose adjustment is necessary for ULORIC when co-administered with hydrochlorothiazide. Administration of ULORIC (80 mg) with hydrochlorothiazide (50 mg) did not result in any clinically significant changes in C<span class="Sub">max</span> or AUC of febuxostat (less than 4%), and serum uric acid concentrations were not substantially affected.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d2c64527-6570-4a37-8936-32b20eec438a"></a><a name="section-11.3.6.3.5"></a><p></p>
<p class="First"><span class="Italics">Warfarin: </span>No dose adjustment is necessary for warfarin when co-administered with ULORIC. Administration of ULORIC (80 mg once daily) with warfarin had no effect on the pharmacokinetics of warfarin in healthy subjects. INR and Factor VII activity were also not affected by the co-administration of ULORIC.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3b3cb744-8ffc-490d-b318-a64e392ad457"></a><a name="section-11.3.6.3.6"></a><p></p>
<p class="First"><span class="Italics">Desipramine: </span>Co-administration of drugs that are CYP2D6 substrates (such as desipramine) with ULORIC are not expected to require dose adjustment. Febuxostat was shown to be a weak inhibitor of CYP2D6 <span class="Italics">in vitro </span>and<span class="Italics"> in vivo</span>. Administration of ULORIC (120 mg once daily) with desipramine (25 mg) resulted in an increase in C<span class="Sub">max</span> (16%) and AUC (22%) of desipramine, which was associated with a 17% decrease in the 2-hydroxydesipramine to desipramine metabolic ratio (based on AUC). </p>
</div>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_86e5fb2d-4547-4b5d-8114-95d72eb41159"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_21f85689-50d9-46f6-aa3b-e24864599cb5"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a7f7c6cc-695d-46b4-8c5c-4d0654b73cf7"></a><a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Italics">Carcinogenesis</span>: Two-year carcinogenicity studies were conducted in F344 rats and B6C3F1 mice. Increased transitional cell <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span> and carcinoma of urinary bladder was observed at 24 mg per kg (25 times the human plasma exposure at maximum recommended human dose of 80 mg per day) and 18.75 mg per kg (12.5 times the human plasma exposure at 80 mg per day) in male rats and female mice, respectively. The urinary bladder neoplasms were secondary to calculus formation in the kidney and urinary bladder.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c7aca54f-36ea-40c5-8dc2-12296138bab0"></a><a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Italics">Mutagenesis</span>: Febuxostat showed a positive mutagenic response in a chromosomal aberration assay in a Chinese hamster lung fibroblast cell line with and without metabolic activation <span class="Italics">in vitro</span>. Febuxostat was negative in the <span class="Italics">in vitro</span> Ames assay and chromosomal aberration test in human peripheral <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell line, and <span class="Italics">in vivo</span> tests in mouse micronucleus, rat unscheduled DNA synthesis and rat bone marrow cells.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f8edf56a-7c40-46a0-81d2-2bd0ec10f48e"></a><a name="section-12.1.3"></a><p></p>
<p class="First"><span class="Italics">Impairment of Fertility:</span> Febuxostat at oral doses up to 48 mg per kg per day (approximately 35 times the human plasma exposure at 80 mg per day) had no effect on fertility and reproductive performance of male and female rats. </p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_75a66a8a-a171-4241-b66d-0b0ebbd78bec"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">A 12-month toxicity study in beagle dogs showed deposition of xanthine crystals and calculi in kidneys at 15 mg per kg (approximately 4 times the human plasma exposure at 80 mg per day). A similar effect of calculus formation was noted in rats in a six-month study due to deposition of xanthine crystals at 48 mg per kg (approximately 35 times the human plasma exposure at 80 mg per day).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_3203497f-1ae2-46f5-86e0-94fb4ebcda25"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">A serum uric acid level of less than 6 mg per dL is the goal of anti-hyperuricemic therapy and has been established as appropriate for the treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8c49e13a-8c1f-4d61-bd86-2eec3d56259a"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Management of <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> in <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout</span></h2>
<p class="First">The efficacy of ULORIC was demonstrated in three randomized, double-blind, controlled trials in patients with <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> and <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>. <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> was defined as a baseline serum uric acid level ≥ 8 mg per dL.</p>
<p>Study 1 randomized patients to: ULORIC 40 mg daily, ULORIC 80 mg daily, or allopurinol (300 mg daily for patients with estimated creatinine clearance (Cl<span class="Sub">cr</span>) ≥ 60 mL per min or 200 mg daily for patients with estimated Cl<span class="Sub">cr</span> ≥ 30 mL per min and ≤ 59 mL per min). The duration of Study 1 was 6 months. </p>
<p>Study 2 randomized patients to: placebo, ULORIC 80 mg daily, ULORIC 120 mg daily, ULORIC 240 mg daily or allopurinol (300 mg daily for patients with a baseline serum creatinine ≤ 1.5 mg per dL or 100 mg daily for patients with a baseline serum creatinine greater than 1.5 mg per dL and ≤ 2 mg per dL). The duration of Study 2 was 6 months.</p>
<p>Study 3, a 1-year study, randomized patients to: ULORIC 80 mg daily, ULORIC 120 mg daily, or allopurinol 300 mg daily. Subjects who completed Study 2 and Study 3 were eligible to enroll in a phase 3 long-term extension study in which subjects received treatment with ULORIC for over three years.</p>
<p>In all three studies, subjects received naproxen 250 mg twice daily or colchicine 0.6 mg once or twice daily for <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flare</span> prophylaxis. In Study 1 the duration of prophylaxis was 6 months; in Study 2 and Study 3 the duration of prophylaxis was 8 weeks.</p>
<p>The efficacy of ULORIC was also evaluated in a 4 week dose ranging study which randomized patients to: placebo, ULORIC 40 mg daily, ULORIC 80 mg daily, or ULORIC 120 mg daily. Subjects who completed this study were eligible to enroll in a long-term extension study in which subjects received treatment with ULORIC for up to five years.</p>
<p>Patients in these studies were representative of the patient population for which ULORIC use is intended. Table 2 summarizes the demographics and baseline characteristics for the subjects enrolled in the studies.</p>
<a name="id_43e0321c-9501-407f-94bf-3a1157ce74e3"></a><table>
<col align="left" width="15%">
<col align="left" width="55%">
<col align="left" width="30%">
<thead><tr class="Botrule First Last"><td class="Lrule Rrule" align="center" colspan="3" valign="top">Table 2: Patient Demographics and Baseline Characteristics in Study 1, Study 2 and Study 3</td></tr></thead>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" colspan="2" valign="top">Male</td>
<td class="Rrule" align="left" valign="top">95%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">Race: </td>
<td class="Rrule" align="left" valign="top">Caucasian</td>
<td class="Rrule" align="left" valign="top">80%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">African American</td>
<td class="Rrule" align="left" valign="top">10%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">Ethnicity: </td>
<td class="Rrule" align="left" valign="top">Hispanic or Latino</td>
<td class="Rrule" align="left" valign="top"> 7%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="top">Alcohol User</td>
<td class="Rrule" align="left" valign="top">67%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="top">Mild to Moderate <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span><br>[percent with estimated Cl<span class="Sub">cr</span> less than 90 mL per min]</td>
<td class="Rrule" align="left" valign="top">59%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="top">History of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule" align="left" valign="top">49%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="top">History of <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></td>
<td class="Rrule" align="left" valign="top">38%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="top">BMI ≥ 30 kg per m<span class="Sup">2</span>
</td>
<td class="Rrule" align="left" valign="top">63%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="top">Mean BMI</td>
<td class="Rrule" align="left" valign="top">33 kg per m<span class="Sup">2</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="top">Baseline sUA ≥ 10 mg per dL</td>
<td class="Rrule" align="left" valign="top">36%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2" valign="top">Mean baseline sUA</td>
<td class="Rrule" align="left" valign="top">9.7 mg per dL</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" colspan="2" valign="top">Experienced a <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flare</span> in previous year</td>
<td class="Rrule" align="left" valign="top">85% </td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eba07419-892b-4ee1-b6c5-7c61c5ff2c06"></a><a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Italics">Serum Uric Acid Level less than 6 mg per dL at Final Visit: </span> ULORIC 80 mg was superior to allopurinol in lowering serum uric acid to less than 6 mg per dL at the final visit. ULORIC 40 mg daily, although not superior to allopurinol, was effective in lowering serum uric acid to less than 6 mg per dL at the final visit (<a href="#id_48390d23-89a5-4d0a-8721-05ad57f4e504">Table 3</a>).</p>
<a name="id_48390d23-89a5-4d0a-8721-05ad57f4e504"></a><table>
<col align="left" width="14%">
<col align="center" width="13%">
<col align="center" width="13%">
<col align="center" width="13%">
<col align="center" width="13%">
<col align="center" width="17%">
<col align="center" width="17%">
<thead>
<tr class="First Toprule"><td class="Botrule Lrule Rrule" align="center" colspan="7" valign="top">Table 3: Proportion of Patients with Serum Uric Acid Levels Less Than 6 mg per dL at Final Visit </td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top">Difference in Proportion<br>(95% CI)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="center" valign="middle">Study<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td class="Rrule" align="center" valign="top">ULORIC<br>40 mg daily</td>
<td class="Rrule" align="center" valign="top">ULORIC<br>80 mg daily</td>
<td class="Rrule" align="center" valign="middle">allopurinol</td>
<td class="Rrule" align="center" valign="middle">Placebo</td>
<td class="Rrule" align="center" valign="top">ULORIC 40 mg<br>vs<br>allopurinol</td>
<td class="Rrule" align="left" valign="top">ULORIC 80 mg<br>vs<br>allopurinol</td>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Randomization was balanced between treatment groups, except in Study 2 in which twice as many patients were randomized to each of the active treatment groups compared to placebo.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top">Study 1<br>(6 months)<br>(N=2268)</td>
<td class="Rrule" align="left" valign="top">45%</td>
<td class="Rrule" align="left" valign="top">67%</td>
<td class="Rrule" align="left" valign="top">42%</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">3%<br>(-2%, 8%)</td>
<td class="Rrule" align="left" valign="top">25%<br>(20%, 30%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Study 2<br>(6 months)<br>(N=643)</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">72%</td>
<td class="Rrule" align="left" valign="top">39%</td>
<td class="Rrule" align="left" valign="top">1%</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">33%<br>(26%, 42%)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">Study 3<br>(12 months)<br>(N=491)</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">74%</td>
<td class="Rrule" align="left" valign="top">36%</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">38%<br>(30%, 46%)</td>
</tr>
</tbody>
</table>
<p>In 76% of ULORIC 80 mg patients, reduction in serum uric acid levels to less than 6 mg per dL was noted by the Week 2 visit. Average serum uric acid levels were maintained at 6 mg per dL or below throughout treatment in 83% of these patients. </p>
<p>In all treatment groups, fewer subjects with higher baseline serum urate levels (≥ 10 mg per dL) and/or tophi achieved the goal of lowering serum uric acid to less than 6 mg per dL at the final visit; however, a higher proportion achieved a serum uric acid less than 6 mg per dL with ULORIC 80 mg than with ULORIC 40 mg or allopurinol. </p>
<p>Study 1 evaluated efficacy in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (i.e., baseline estimated Cl<span class="Sub">cr </span>less than 90 mL per minute). The results in this sub-group of patients are shown in Table 4.</p>
<a name="id_83eeed1f-d2b7-4e9c-9eb2-47600ee4edf7"></a><table>
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<thead>
<tr class="First Toprule"><td class="Botrule Lrule Rrule" align="center" colspan="5" valign="top">Table 4: Proportion of Patients with Serum Uric Acid Levels Less Than 6 mg per dL in Patients with Mild or Moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> at Final Visit </td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top">Difference in Proportion <br> (95% CI)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">ULORIC<br>40 mg daily<br>(N=479)</td>
<td class="Rrule" align="left" valign="top">ULORIC<br>80 mg daily<br>(N=503)</td>
<td class="Rrule" align="left" valign="top">allopurinol<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a><br>300 mg daily<br>(N=501)</td>
<td class="Rrule" align="left" valign="top">ULORIC 40 mg vs allopurinol</td>
<td class="Rrule" align="left" valign="top">ULORIC 80 mg vs allopurinol</td>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Allopurinol patients (n=145) with estimated Cl<span class="Sub">cr</span> ≥ 30 mL per min and Cl<span class="Sub">cr </span> ≤ 59 mL per min were dosed at 200 mg daily.</dd>
</dl></td></tr></tfoot>
<tbody><tr class="Botrule First Last">
<td class="Lrule Rrule" align="center" valign="top">50%</td>
<td class="Rrule" align="center" valign="top">72%</td>
<td class="Rrule" align="center" valign="top">42%</td>
<td class="Rrule" align="left" valign="top">7%<br>(1%, 14%)</td>
<td class="Rrule" align="left" valign="top">29%<br>(23%, 35%)</td>
</tr></tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_e6edeb43-4d88-4ff8-85ad-8acec00f74ec"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">ULORIC 80 mg tablets are light green to green in color, teardrop shaped, debossed with "TAP" on one side and "80" on the other side and supplied as:</p>
<a name="id_33c79238-0990-44f1-971b-f23e706c0bea"></a><table>
<col align="left" width="40%">
<col align="left" width="60%">
<thead><tr class="Botrule First Last">
<td class="Rrule" align="left" valign="top"><span class="Underline">NDC Number</span></td>
<td align="left" valign="top"><span class="Underline">Size</span></td>
</tr></thead>
<tbody><tr class="Botrule First Last">
<td align="left" valign="top">21695-516-30</td>
<td align="left" valign="top">Bottle of 30 Tablets</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_2edc789d-10bc-49ad-b8c1-acea0f26927c"></a><a name="section-14.1"></a><p></p>
<p class="First">Protect from light. Store at 25°C (77°F); excursions permitted to 15°– 30°C (59°– 86°F) [See USP Controlled Room Temperature]</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_f10cdeca-94de-4f30-9c18-c76e0e2c8ca7"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">[see <a href="#i4i_section_id_7bd5fc3d-3c05-4e0e-8707-8740e7f762f1">FDA-Approved Patient Labeling (17.2)</a>]</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6e76cb82-18ee-4377-9680-1bf2399f8adf"></a><a name="section-15.1"></a><p></p>
<h2>17.1 General Information</h2>
<p class="First">Patients should be advised of the potential benefits and risks of ULORIC. Patients should be informed about the potential for <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>, elevated liver enzymes and adverse cardiovascular events after initiation of ULORIC therapy. </p>
<p>Concomitant prophylaxis with an NSAID or colchicine for <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> should be considered.</p>
<p>Patients should be instructed to inform their healthcare professional if they develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span> suggesting a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. Patients should be instructed to inform their healthcare professional of any other medications they are currently taking with ULORIC, including over-the-counter medications.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7bd5fc3d-3c05-4e0e-8707-8740e7f762f1"></a><a name="section-15.2"></a><p></p>
<h2>17.2 FDA-Approved Patient Labeling </h2>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_53209396-c723-4b34-9021-3045d2d47ee1"></a><a name="section-16"></a><p></p>
<p class="First">Patient Information<br><span class="Bold">ULORIC<span class="Sup">®</span></span> (Ū – 'lor – ik)<br>(febuxostat) tablets</p>
<p>Read the Patient Information that comes with ULORIC before you start taking it and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment. </p>
<p><span class="Bold">What is ULORIC?</span></p>
<p>ULORIC is a prescription medicine called a xanthine oxidase (XO) inhibitor, used to lower blood uric acid levels in adults with <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>.</p>
<p>It is not known if ULORIC is safe and effective in children under 18 years of age.</p>
<p><span class="Bold">Who should not take ULORIC?</span></p>
<p><span class="Bold">Do not take ULORIC if you: </span></p>
<ul>
<li>take Azathioprine (Azasan<span class="Sup">®</span>, Imuran<span class="Sup">®</span>)</li>
<li>take Mercaptopurine (Purinethol<span class="Sup">®</span>) </li>
<li>take Theophylline (Theo-24<span class="Sup">®</span>, Elixophyllin<span class="Sup">®</span>, Theochron<span class="Sup">®</span>, Theolair<span class="Sup">®</span>, Uniphyl<span class="Sup">®</span>)</li>
</ul>
<p>It is not known if ULORIC is safe and effective in children under 18 years of age.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking ULORIC?</span></p>
<p>Before taking ULORIC tell your healthcare provider about all of your medical conditions, including if you:</p>
<ul>
<li>have liver or kidney problems</li>
<li>have a history of heart disease or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>are pregnant or plan to become pregnant. It is not known if ULORIC will harm your unborn baby. Talk with your healthcare provider if you are pregnant or plan to become pregnant.</li>
<li>are breast-feeding or plan to breast-feed. It is not known if ULORIC passes into your breast milk. You and your healthcare provider should decide if you should take ULORIC while breast-feeding.</li>
</ul>
<p>Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. ULORIC may affect the way other medicines work, and other medicines may affect how ULORIC works.</p>
<p>Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take ULORIC? </span></p>
<ul>
<li>Take ULORIC exactly as your healthcare provider tells you to take it.</li>
<li>ULORIC can be taken with or without food.</li>
<li>ULORIC can be taken with antacids.</li>
<li>Your <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> may flare up when you start taking ULORIC, do not stop taking your ULORIC even if you have a flare. Your healthcare provider may give you other medicines to help prevent your <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>.</li>
<li>Your healthcare provider may do certain tests while you take ULORIC.</li>
</ul>
<p><span class="Bold">What are the possible side effects of ULORIC? </span></p>
<p>Heart problems. A small number of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and heart-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were seen in clinical studies. It is not certain that ULORIC caused these events.</p>
<p>The most common side effects of ULORIC include:</p>
<ul>
<li>liver problems</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span></li>
<li><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> </li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of ULORIC. For more information, ask your healthcare provider or pharmacist. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">How should I store ULORIC? </span></p>
<p>Store ULORIC between 59°F - 86°F (15°C - 30°C).</p>
<p>Keep ULORIC out of the light. </p>
<p>Keep ULORIC and all medicines out of the reach of children. </p>
<p><span class="Bold">General information about the safe and effective use of ULORIC</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Do not use ULORIC for a condition for which it was not prescribed. Do not give ULORIC to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This patient information leaflet summarizes the most important information about ULORIC. If you would like more information about ULORIC talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about ULORIC that is written for health professionals. For more information go to www.uloric.com, or call 1-877-825-3327.</p>
<p><span class="Bold">What are the ingredients in ULORIC?</span></p>
<p>Active Ingredient: febuxostat </p>
<p>Inactive ingredients include: lactose monohydrate, microcrystalline cellulose, hydroxypropyl cellulose, sodium croscarmellose, silicon dioxide, magnesium stearate, and Opadry II, green</p>
<p>Distributed by<br><span class="Bold">Takeda Pharmaceuticals America, Inc. </span><br>Deerfield, IL 60015</p>
<p>U.S. Patent Nos. - 6,225,474; 7,361,676; 5,614,520. </p>
<p>ULORIC<span class="Sup">®</span> is a registered trademark of Teijin Pharma Limited and used under license by Takeda Pharmaceuticals America, Inc.</p>
<p>All other trademark names are the property of their respective owners</p>
<p>©2009 Takeda Pharmaceuticals America, Inc.</p>
<p>PI1114 R1<br>February 2009</p>
<p>Repackaged by <span class="Bold">Rebel Distributors Corp</span></p>
<p>Thousand Oaks, CA 91320</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_id_5fe6be53-f6d9-452d-a604-985200a6bc89"></a><a name="section-17"></a><p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_fe2e802c-63a7-487a-ab2a-6d61aa093839"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 80 mg 30 Tablet Bottle</span></p>
<p>30 Tablets<br><span class="Bold">Rx only</span></p>
<p><span class="Bold"><span class="Italics">Uloric</span><span class="Sup">®</span></span><br>febuxostat<br>tablets </p>
<p><span class="Bold">80 mg</span></p>
<p>   </p>
<div class="Figure">
<img alt="Uloric 80 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ae1e0d8a-03fc-419b-9d44-afa68fbd5681&amp;name=ae1e0d8a-03fc-419b-9d44-afa68fbd5681-02.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ULORIC 		
					</strong><br><span class="contentTableReg">febuxostat tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:21695-516(NDC:64764-677)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>febuxostat</strong> (febuxostat) </td>
<td class="formItem">febuxostat</td>
<td class="formItem">80 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydroxypropyl cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN (light green to green) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">TEAR (teardrop shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TAP;80</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:21695-516-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021856</td>
<td class="formItem">02/13/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Rebel Distributors Corp
							(118802834)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Rebel Distributors Corp</td>
<td class="formItem"></td>
<td class="formItem">118802834</td>
<td class="formItem">RELABEL, REPACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ae1e0d8a-03fc-419b-9d44-afa68fbd5681</div>
<div>Set id: ae1e0d8a-03fc-419b-9d44-afa68fbd5681</div>
<div>Version: 1</div>
<div>Effective Time: 20101227</div>
</div>
</div> <div class="DistributorName">Rebel Distributors Corp</div></p>
</body></html>
